Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Protocol Amendment History 51 amendments
This ClinicalTrials.gov record has been amended 51 times since 2023-08-30; most recent amendment 2026-04-22.
Status change: Recruiting → Active, Not Recruiting 2025-12-15
Status change: Not Yet Recruiting → Recruiting 2023-11-13
Trial Details
NCT Number NCT06025578
Lead Sponsor Bristol-Myers Squibb
Conditions Progressive Pulmonary Fibrosis
Enrollment 1,057 participants
Start Date 2023-10-25
Primary Completion 2027-12-27 (estimated)
Study Completion 2027-12-27 (estimated)
Updated on ClinicalTrials.gov 2026-04-23